• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by AN2 Therapeutics Inc.

    3/13/26 5:02:05 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    AN2 Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)




    03/06/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Integrated Core Strategies (US) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,135,044.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,135,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,135,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,237,102.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,237,102.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,237,102.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,237,102.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,237,102.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,237,102.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,237,102.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,237,102.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,237,102.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AN2 Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1300 El Camino Real, Suite 100, Menlo Park, California 94025
    Item 2. 
    (a)Name of person filing:

    Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    037326105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page. The percent of class was calculated based on 35,647,635 shares of Common Stock outstanding, which is the sum of (i) 27,402,024 shares of Common Stock outstanding as of November 3, 2025, as reported in the issuer's Form 10-Q filed with the SEC on November 12, 2025, and (ii) 8,245,611 shares of Common Stock issued in connection with a private placement that closed on or about March 10, 2026, as reported in the issuer's Form 8-K filed with the SEC on March 10, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Integrated Core Strategies (US) LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:03/12/2026
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:03/12/2026
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:03/12/2026
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:03/12/2026

    Comments accompanying signature:  ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of March 12, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $ANTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANTX

    DatePrice TargetRatingAnalyst
    8/9/2024In-line → Underperform
    Evercore ISI
    8/9/2024$5.00 → $1.00Outperform → Market Perform
    Leerink Partners
    7/3/2024$5.00Market Perform → Outperform
    Leerink Partners
    4/2/2024$6.00Mkt Perform → Mkt Outperform
    JMP Securities
    2/13/2024$23.00 → $7.00Outperform → Market Perform
    Leerink Partners
    2/12/2024$25.00 → $7.00Outperform → In-line
    Evercore ISI
    2/12/2024Outperform → Perform
    Oppenheimer
    2/12/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $ANTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS), for the treatment of pulmonary disease caused by Mycobacterium abscessus (M. abscessus). The 84-patient, multicenter, randomized, double-blind study is being led by Dr. Kevin Winthrop at Oregon Health & Science University (OHSU), in collaboration with other investigators across an estimated 10-15 sites in th

    3/31/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

    Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline results anticipated in late 2027 Chagas disease program progresses as Phase 1 first-in-human trial of oral AN2-502998 nears completion with initial clinical data expected in 1Q26; Initiation of Phase 2 proof-of-concept study in patients with chronic Chagas disease planned for 2026 pending results On track to advance two boron-based oncology compounds into development in 2026 March 20

    3/17/26 4:00:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Announces $40 Million Private Placement Financing

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share and, in lieu of common stoc

    3/9/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    SEC Filings

    View All

    SEC Form D filed by AN2 Therapeutics Inc.

    D - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/25/26 4:42:23 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by AN2 Therapeutics Inc.

    8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/20/26 4:37:10 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by AN2 Therapeutics Inc.

    S-8 - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/17/26 4:10:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AN2 Therapeutics downgraded by Evercore ISI

    Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform

    8/9/24 8:39:40 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously

    8/9/24 7:16:36 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00

    7/3/24 7:25:34 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    6/3/25 4:46:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fitzpatrick Margaret M bought $10,133 worth of shares (8,610 units at $1.18) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    5/29/25 4:17:48 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Readnour Robin Shane bought $86,708 worth of shares (60,000 units at $1.45) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    12/10/24 8:46:19 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Day Lucy

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/23/26 7:16:42 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chanda Sanjay

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/23/26 7:16:39 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Marks Gilbert Lynn

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/23/26 7:13:56 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Leadership Updates

    Live Leadership Updates

    View All

    Brii Biosciences Provides Latest Clinical Development and Corporate Updates

    Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

    7/5/23 7:18:00 PM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

    AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a

    5/9/22 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Financials

    Live finance-specific insights

    View All

    AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all

    8/16/24 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

    Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi

    3/28/24 4:10:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

    Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

    3/22/24 7:00:00 AM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ANTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:29:18 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:16:45 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/13/24 4:25:27 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care